GOVX Stock — GeoVax Labs Inc.: Cash, EV, Pipeline

Share price

$0.36

Market cap

$3.6M

Cash

$3.1M

Enterprise value

$0.5M

Balance sheet

Cash	$3.1M
Debt	$0.0M
Net cash	$3.1M
Enterprise value	$0.5M
Basic shares	7.4M shares
Fully diluted shares	16.2M shares
Fully diluted market cap	$5.8M
Cash per share	$0.42

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GOVX daily closes…

Loading price history…

Pipeline assets

GEO-MVA

Phase 3 · Active Modality: vaccine (Modified Vaccinia Ankara)

Target Orthopoxvirus (mpox/smallpox)

Indications

Mpox and smallpox (Phase 3)

Catalysts

— H2 2026

Status note Company's primary near-term strategic priority. EMA scientific advice received May 2025. cGMP clinical drug substance batch produced; continuous avian cell line manufacturing platform under development.

Gedeptin

Phase 2 · Active Modality: oncolytic gene-directed therapy

Indications

Advanced head and neck squamous cell carcinoma (Phase 2)

Catalysts

— 2027

Status note Completed multicenter Phase 1/2 trial (NCT03754933) in advanced HNSCC, partly funded by FDA Orphan Products Clinical Trials Grants Program.

GEO-CM04S1

Phase 2 · Terminated Modality: vaccine (multi-antigen)

Target SARS-CoV-2 spike and nucleocapsid

Partnerships BARDA (via Rapid Response Partnership Vehicle consortium): award Jun 2024 to advance GEO-CM04S1 Phase 2b trial

Indications

COVID-19 (Phase 2)

Status note Discontinued May 26, 2026 as part of strategic reprioritization (not safety-related); BARDA contract terminated for convenience in April 2025.

Per-asset detail extracted from the 10-Q filed 2026-07-27. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	COVID-19 Vaccine
Lead indication	COVID-19 Infection
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04977024	Phase 2	Active, not recruiting	Sponsor	GeoVax, Inc.	—	COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for GeoVax, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

GOVX — GeoVax Labs Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials